News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 5, 2024

Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

Key opinion leaders explore molecular characteristics beyond mutations that influence immunotherapy response in non small cell lung cancer treatment.

Episodes in this series

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

A panel of 4 experts on lung cancer

EP. 11 Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

A panel of 4 experts on lung cancer

EP. 12 Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

A panel of 4 experts on lung cancer

EP. 13 Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

Beyond genomic mutations like STK11/KEAP1/KRAS, are there other molecular characteristics that can influence immunotherapy effectiveness and should guide treatment selection?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Inside the Pivotal Trials Shaping Vitiligo Treatment Choices

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

August 26th 2026

Payer Perspectives on Topical Versus Oral JAK Selectivity

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

August 26th 2026

5 experts are featured in this series

Catching Alzheimer's Disease Early: Assessing Mild Cognitive Impairment in Primary Care

ByKavita Nair, PhD,Joshua Oaks, MD,Scott Joy, MD, MBA, FACP,Jennifer Woodward, MD, MPH,Dylan Gallacher, PA

August 25th 2026

5 experts are featured in this series

Alzheimer's Disease Prevalence and Prevention: Building the Case for Early Diagnosis

ByKavita Nair, PhD,Joshua Oaks, MD,Scott Joy, MD, MBA, FACP,Jennifer Woodward, MD, MPH,Dylan Gallacher, PA

August 25th 2026

Complementary, Not Competing: How an Endocrinologist Compares Dual Incretin Approaches for Obesity and MASH

ByJaime Almandoz, MD, MBA

August 21st 2026

Trending on AJMC

US Employer Health Care Costs Projected to Rise 9.5% in 2027

FDA Clears First Single-Biomarker Blood Test for Alzheimer

Lung Cancer Task Force Maps Research Roadmap to Close Survival Gap

FDA Approves Nipocalimab-aahu as First Treatment for wAIHA

New York Experts Push for Coordinated Obesity Care Teams